RFK Jr.’s HHS Leadership Shows Divergent Views on Pharma Regulation
Washington D.C. – A recent forum hosted by the Pharmaceutical Research and Manufacturers of America (PhRMA) highlighted differing perspectives among key figures within the Biden administration regarding pharmaceutical regulation and vaccine policy. The event showcased contrasting viewpoints from Centers for Medicare and Medicaid Services Administrator Mehmet Oz and Food and Drug Administration (FDA) Commissioner Marty Makary, both serving as top lieutenants to Health and Human Services Secretary Robert F. Kennedy Jr.
Oz Signals Collaboration, Raises Revolving Door Concerns
Dr. Mehmet Oz engaged in a cordial conversation with Pfizer CEO and PhRMA board chair Albert Bourla, expressing support for the benefits of vaccines and openness to closed-door meetings between industry executives and policymakers to develop new policy initiatives. Notably, Oz suggested that industry leaders consider taking on roles within the government, a statement that appears to contradict Kennedy Jr.’s past criticisms of the “revolving door” phenomenon – the movement of personnel between government and the private sector. [Source: archyde.com]
Makary Faces Scrutiny on Vaccine Regulation
Food and Drug Administration Commissioner Marty Makary faced questioning from former CNBC reporter Bertha Coombs regarding the agency’s approach to vaccine regulation, including the recent decision by a top official to refuse review of Moderna’s application for a new flu shot. [Source: archyde.com]
PhRMA Engagement with the Trump Administration
As the second Trump administration settles in, PhRMA leaders prepared to meet with President Trump in February 2025 to discuss policy affecting the industry. A key goal for the industry is to garner support for adjustments to certain drug pricing provisions within the 2022 Inflation Reduction Act. [Source: fiercepharma.com]
Bourla Expresses Optimism for Collaboration
Pfizer CEO Albert Bourla, recently appointed as PhRMA’s new chair, expressed optimism about potential collaboration with Robert F. Kennedy Jr. Bourla stated that he and Kennedy had dinner together, facilitated by former President Donald Trump, where they discussed areas of agreement such as chronic diseases, cardiovascular health, and cancer research. [Source: qz.com] Bourla also indicated that Kennedy appeared to have “tempered” his past statements on vaccines during recent hearings. [Source: qz.com]
Bourla’s Perspective on Kennedy’s HHS Leadership
While acknowledging that Robert F. Kennedy Jr. Was not his “first choice” for HHS Secretary, Bourla believes there are areas where Pfizer and the administration can “collaborate,” such as combating chronic diseases. [Source: msn.com] He highlighted his longstanding relationship with President Trump, established during Operation Warp Speed, as a potential asset in navigating the new political landscape. [Source: msn.com]